Back to Trial

Oracle Runs

Oracle findings and outcome history for A Trial of SHR0302Base in Patients With Vitiligo (NCT06790862).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT06790862 remains active not recruiting as of April 2026, with estimated primary completion March 2026. No public results, topline readouts, or efficacy data found across web searches. All sources confirm ongoing status without outcome framing.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
Web Searchclinicaltrials.govApr 6, 2026, 12:00 AM
A Trial of SHR0302Base in Patients With Vitiligo
Active, not recruiting. Estimated primary completion 2026-03-03. No results posted.
Web Searchichgcp.netJan 13, 2026, 12:00 AM
SHR0302Base gel in Vitiligo - Clinical Trials Registry
Updated January 2026 by sponsor. Multicenter phase 2 trial ongoing.
Web Searchvrfoundation.orgJan 2, 2026, 12:00 AM
Vitiligo Drug Pipeline Analysis - January 2026
SHR0302Base (Topical JAK1 inhibitor): Global Phase 2 trials for vitiligo ongoing.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public results posted; trial active/not recruiting with primary completion estimated 2026-03. No sponsor press release, topline data, or source frames this exact Phase 2 (NCT06790862) as positive/negative. Prior related topical SHR0302 (ARQ-252) program had formulation issues and early termination (different trial). Pipeline listings only note ongoing Phase 2 without outcomes.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
A Trial of SHR0302Base in Patients With Vitiligo
Current status: Active, not recruiting. Estimated primary completion: 2026-03-03. Primary endpoint: proportion achieving F-VASI50 at week 24. No results posted.
Web Searchvrfoundation.orgJan 2, 2026, 12:00 AM
Vitiligo Drug Pipeline Analysis - January 2026
SHR0302Base (Topical JAK1 inhibitor): Global Phase 2 trials for vitiligo. No published results as of Jan 2026 for related completed Phase 2 (different NCT).
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govJan 15, 2026, 12:00 AM
Study Details | NCT06790862 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-03-03; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. The cited registry mirrors still list NCT06790862/SHR0302Base-201 as Phase 2 and active, not recruiting in 2026, which supports that a positive/negative public outcome has not yet been clearly reported for this exact trial.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsctv.veeva.com
A Trial of SHR0302Base in Patients With Vitiligo
Study page for NCT06790862 shows Status: Active, not recruiting; Phase 2; sponsor Hengrui; evaluates SHR0302Base gel vs placebo in nonsegmental vitiligo.
Web Searchtriallayer.com
NCT06790862: A Multicenter, Randomized, Double-blind, Parallel, Excipient-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR0302Base
TrialLayer, sourced from ClinicalTrials.gov, lists NCT06790862 as ACTIVE_NOT_RECRUITING, PHASE2, with completion date 2026-04-30 and no readout language.
NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear public Phase 2 readout was found for this exact trial. ClinicalTrials.gov still showed no posted results after the estimated primary completion date, and Hengrui’s 2025 interim pipeline disclosure still listed SHR0302 for non-segmental vitiligo as Phase II with no reported progress/readout.

Found Apr 1, 2026, 7:52 PMReviewed Apr 1, 2026, 7:56 PM
ClinicalTrialsclinicaltrials.govJan 15, 2026, 12:00 AM
Study Details | NCT06790862 | A Trial of SHR0302Base in Patients With Vitiligo | ClinicalTrials.gov
ClinicalTrials.gov lists NCT06790862 with estimated primary completion of 2026-03-03 and explicitly shows 'No Results Posted.'
Sponsorhkexnews.hkSep 26, 2025, 12:00 AM
Hengrui Pharmaceuticals 2025 Interim Report
Hengrui’s interim report lists SHR0302 (mono, alkaline gel) for non-segmental vitiligo in Phase II; the table notes 'Progress during the Reporting Period: None.'
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.